Table 3.

Subsequent second-line anticancer treatments after stabilized inverse probability of treatment weighting analysis.

Treatments, n (%)	Palbociclib + aromatase inhibitor (n = 1572)	Aromatase inhibitor alone (n = 1137)
First-line treatment only (patients who continued treatment, died, or were censored in the first-line setting)	804 (51.1)	396 (34.8)
Any second-line treatment (patients could have received >1 category of second-line treatment)	768 (48.9)	741 (65.1)
Cyclin-dependent kinase 4/6 inhibitor	331 (43.1)	374 (50.5)
Chemotherapy	162 (21.1)	112 (15.1)
Endocrine therapy alone	154 (20.1)	225 (30.4)
Other anticancer treatment	164 (21.4)	94 (12.7)